Arcus Biosciences, Inc. Earnings Per Share (Diluted)
Arcus Biosciences, Inc. (RCUS) reported Earnings Per Share (Diluted) of -$0.72 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-05
- Arcus Biosciences, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.72.
- Arcus Biosciences, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$1.02.
- Arcus Biosciences, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.89.
- Arcus Biosciences, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$1.27.
- Arcus Biosciences, Inc. earnings per share, diluted for fiscal 2025 was -$3.29.
- Arcus Biosciences, Inc. earnings per share, diluted for fiscal 2024 was -$3.14.
- Arcus Biosciences, Inc. earnings per share, diluted for fiscal 2023 was -$4.15.
- Arcus Biosciences, Inc. earnings per share, diluted for fiscal 2022 was -$3.71, a 622.54% decline from fiscal 2021.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.72 10-Q · filed 2026-08-05 | -$1.74 10-Q · filed 2026-08-05 | -$2.64 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.86 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$1.02 10-Q · filed 2026-05-05 | -$1.92 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.16 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.23 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | -$0.89 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.14 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.18 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.29 10-K · filed 2026-02-25 |
| 2025-09-30 | -$1.27 10-Q · filed 2025-10-28 | -$1.27 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.39 10-Q · filed 2025-10-28 | -$3.38 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | -$1.09 10-Q · filed 2026-08-05 | -$2.08 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.07 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$1.14 10-Q · filed 2026-05-05 | -$2.17 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.18 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$4.20 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2024-12-31 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.03 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$3.05 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$3.14 10-K · filed 2026-02-25 |
| 2024-09-30 | -$1.00 10-Q · filed 2025-10-28 | -$2.03 derived: net income ÷ weighted average shares · filed 2025-10-28 | -$2.11 10-Q · filed 2025-10-28 | -$3.14 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2024-06-30 | -$1.02 10-Q · filed 2025-08-06 | -$1.09 10-Q · filed 2025-08-06 | -$2.11 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$3.04 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2024-03-31 | -$0.05 10-Q · filed 2025-05-06 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.98 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.99 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2023-12-31 | -$1.08 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.03 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$3.05 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$4.15 10-K · filed 2026-02-25 |
| 2023-09-30 | -$0.94 10-Q · filed 2024-11-06 | -$1.98 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$3.07 10-Q · filed 2024-11-06 | -$3.99 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2023-06-30 | -$1.04 10-Q · filed 2024-08-08 | -$2.13 10-Q · filed 2024-08-08 | -$3.04 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$3.95 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2023-03-31 | -$1.09 10-Q · filed 2024-05-08 | -$2.02 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.92 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$3.85 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2022-12-31 | -$0.92 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.82 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.76 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$3.71 10-K · filed 2025-02-25 |
| 2022-09-30 | -$0.90 10-Q · filed 2022-11-02 | -$1.83 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$2.78 10-Q · filed 2022-11-02 | $1.05 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2022-06-30 | -$0.93 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1.89 derived: net income ÷ weighted average shares · filed 2023-08-07 | $1.87 derived: net income ÷ weighted average shares · filed 2026-04-21 | $0.88 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2022-03-31 | -$0.96 derived: net income ÷ weighted average shares · filed 2023-11-07 | $2.64 derived: net income ÷ weighted average shares · filed 2026-04-21 | $1.74 derived: net income ÷ weighted average shares · filed 2026-04-21 | |
| 2021-12-31 | $3.14 derived: net income ÷ weighted average shares · filed 2026-04-21 | $2.53 derived: net income ÷ weighted average shares · filed 2026-04-21 | $0.71 10-K · filed 2024-02-21 | |
| 2021-09-30 | -$1.11 10-Q · filed 2022-11-02 | -$3.28 10-Q · filed 2022-11-02 | ||
| 2020-12-31 | -$0.82 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$0.78 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$1.61 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$2.24 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.03 10-Q · filed 2021-11-08 | -$0.76 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$1.37 10-Q · filed 2021-11-08 | -$1.73 derived: net income ÷ weighted average shares · filed 2022-02-23 |
| 2020-06-30 | -$0.93 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$1.57 derived: net income ÷ weighted average shares · filed 2021-08-05 | -$1.96 derived: net income ÷ weighted average shares · filed 2022-02-23 | -$2.47 derived: net income ÷ weighted average shares · filed 2022-02-23 |
| 2020-03-31 | -$0.63 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$1.00 derived: net income ÷ weighted average shares · filed 2022-02-23 | -$1.51 derived: net income ÷ weighted average shares · filed 2022-02-23 | |
| 2019-12-31 | -$0.38 derived: net income ÷ weighted average shares · filed 2022-02-23 | -$0.89 derived: net income ÷ weighted average shares · filed 2022-02-23 | -$1.93 10-K · filed 2022-02-23 | |
| 2019-09-30 | -$0.51 10-Q · filed 2020-11-05 | -$1.56 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |